Mr. Robert Thast reports

IZOTROPIC CORPORATION UNAWARE OF ANY MATERIAL CHANGE

Izotropic Corp. wishes to confirm that its management is unaware of any material change in the company's operations that would account for the recent increase in market activity.

Izotropic is engaged in the commercialization of proprietary diagnostic products for breast cancer. Its business strategy is to complete the commercial development of 360-degree, true three-dimensional breast-imaging technology for early diagnosis of breast cancer. The company holds a licence under a licence agreement to make, have made, use, offer for sale, import and sell products and services and to practice processes and methods in the field of human diagnostics and therapeutics in the United States and any other countries where approvals are granted or where patent rights may exist in the future with respect to certain licensed patent rights.

About Izotropic Corp.

Izotropic and its wholly owned U.S. operating subsidiary, Izotropic Imaging Corp., have been established to commercialize the next generation of breast-imaging technology for early diagnosis of breast cancer.